Chris Heberlig Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Chris Heberlig.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Chris Heberlig. Chris Heberlig is SVP, Finance & Business Ops. in SYNAGEVA BIOPHARMA CORP ($GEVA) and SVP, Finance and Business Ops. in SYNAGEVA BIOPHARMA CORP ($GEVA) and President and CFO in ORGANOVO HOLDINGS, INC. ($ONVO) and EVP & CFO in Kiniksa Pharmaceuticals, Ltd. ($KNSA) and Exec VP & CFO in Kiniksa Pharmaceuticals, Ltd. ($KNSA).
Latest Insider Trading Transactions of Chris Heberlig
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, KNSA, ONVO, GEVA
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 17 2020 | ONVO | ORGANOVO HOLDINGS, ... | Heberlig Chris | President and CFO | Option Exercise | A | 7.64 | 20,000 | 152,800 | 20,000 | |
| Sep 19 2019 | KNSA | Kiniksa Pharmaceut ... | Heberlig Chris | EVP & CFO | Option Exercise | A | 8.83 | 50,000 | 441,500 | 50,000 | |
| Mar 06 2019 | KNSA | Kiniksa Pharmaceut ... | Heberlig Chris | EVP & CFO | Option Exercise | A | 17.92 | 46,000 | 824,320 | 46,000 | |
| Sep 24 2018 | KNSA | Kiniksa Pharmaceut ... | Heberlig Chris | EVP & CFO | Option Exercise | A | 30.93 | 45,000 | 1,391,850 | 45,000 | |
| May 29 2018 | KNSA | Kiniksa Pharmaceut ... | Heberlig Chris | Exec VP & CFO | Option Exercise | C | 0.00 | 74,935 | 0 | 440,920 | |
| May 29 2018 | KNSA | Kiniksa Pharmaceut ... | Heberlig Chris | Exec VP & CFO | Option Exercise | C | 0.00 | 6,392 | 0 | 0 | |
| May 29 2018 | KNSA | Kiniksa Pharmaceut ... | Heberlig Chris | Exec VP & CFO | Option Exercise | C | 0.00 | 74,935 | 0 | 0 | |
| May 29 2018 | KNSA | Kiniksa Pharmaceut ... | Heberlig Chris | Exec VP & CFO | Option Exercise | P | 0.00 | 6,392 | 0 | 6,392 | |
| May 29 2018 | KNSA | Kiniksa Pharmaceut ... | Heberlig Chris | Exec VP & CFO | Buy | C | 0.00 | 6,392 | 0 | 42,991 | 36.6 K to 43 K (+17.46 %) |
| Jun 23 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | SVP, Finance & Busi ... | Option Exercise | D | 80.35 | 12,000 | 964,200 | 0 | |
| Jun 23 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | SVP, Finance & Busi ... | Option Exercise | D | 40.74 | 7,500 | 305,550 | 0 | |
| Jun 23 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | SVP, Finance & Busi ... | Option Exercise | D | 40.32 | 12,500 | 504,000 | 0 | |
| Jun 23 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | SVP, Finance & Busi ... | Option Exercise | D | 23.00 | 5,000 | 115,000 | 0 | |
| Jun 23 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | SVP, Finance & Busi ... | Option Exercise | D | 1.70 | 838 | 1,425 | 0 | |
| Jun 23 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | SVP, Finance & Busi ... | Option Exercise | D | 0.95 | 82 | 78 | 0 | |
| Jun 23 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | SVP, Finance & Busi ... | Sell | D | 0.00 | 24,000 | 0 | 0 | 24 K to 0 (-100.00 %) |
| Jun 23 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | SVP, Finance & Busi ... | Sell | D | 0.00 | 446 | 0 | 24,000 | 24.4 K to 24 K (-1.82 %) |
| Jun 23 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | SVP, Finance & Busi ... | Grant | A | 78.87 | 56 | 4,417 | 24,446 | 24.4 K to 24.4 K (+0.23 %) |
| Jun 09 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | SVP, Finance & Busi ... | Grant | A | 0.00 | 24,000 | 0 | 24,390 | 390 to 24.4 K (+6,153.85 %) |
| Mar 13 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | SVP, Finance and Bu ... | Option Exercise | M | 40.74 | 7,500 | 305,550 | 7,500 | |
| Mar 13 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | SVP, Finance and Bu ... | Sell | S | 105.74 | 300 | 31,722 | 390 | 690 to 390 (-43.48 %) |
| Mar 13 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | SVP, Finance and Bu ... | Sell | S | 104.57 | 1,510 | 157,901 | 690 | 2.2 K to 690 (-68.64 %) |
| Mar 13 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | SVP, Finance and Bu ... | Sell | S | 103.55 | 3,290 | 340,680 | 2,200 | 5.5 K to 2.2 K (-59.93 %) |
| Mar 13 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | SVP, Finance and Bu ... | Sell | S | 102.46 | 900 | 92,214 | 5,490 | 6.4 K to 5.5 K (-14.08 %) |
| Mar 13 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | SVP, Finance and Bu ... | Sell | S | 101.38 | 600 | 60,828 | 6,390 | 7 K to 6.4 K (-8.58 %) |
| Mar 13 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | SVP, Finance and Bu ... | Sell | S | 100.44 | 900 | 90,396 | 6,990 | 7.9 K to 7 K (-11.41 %) |
| Mar 13 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | SVP, Finance and Bu ... | Buy | M | 40.74 | 7,500 | 305,550 | 7,890 | 390 to 7.9 K (+1,923.08 %) |
| Mar 13 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | SVP, Finance and Bu ... | Grant | A | 76.88 | 86 | 6,612 | 390 | 304 to 390 (+28.29 %) |
Page: 1